SCHEMBL2518142

SCHEMBL2518142

Nc1nsnc1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804589 0.81 LDHA (0.46)
Hydrochloric Acid SCHEMBL7529766 0.78 TDP1 (0.44)
SCHEMBL23925923 0.75 THRB (0.43)
SCHEMBL23939769 0.73 KDM4E (0.58)
SCHEMBL4115514 0.73 KDM4E (0.49)
SCHEMBL2573610 0.72
SCHEMBL3977216 0.70
SCHEMBL21410622 0.70
SCHEMBL16389627 0.70
SCHEMBL588905 0.67 TDP1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259169-A1 PYRIMIDINE BASED MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
US-20240158385-A1 NOVEL COMPOUNDS Cerevance, Inc. 2024-05-16 US disclosed
EP-4288433-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2023-12-13 EP disclosed
CN-116981665-A Novel compounds 思瑞万斯公司 2023-10-31 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2022167819-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2022-08-11 WO disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
US-11192868-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2021-12-07 US disclosed
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-10-21 US disclosed
US-11078168-B2 Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase Phenex Discovery Verwaltungs-GmbH (DE) 2021-08-03 US disclosed
US-20020095033-A1 Monocyclic L-nucleosides, analogs and uses thereof ICN PHARMACEUTICALS, INC. 2002-07-18 US disclosed
US-6323208-B1 COMPOUNDS TO TREAT NEURODEGENERATIVE, PSYCHOTROPIC DRUG AND ALCOHOL INDUCED CENTRAL AND INDUCED CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS. PFIZER INC 2001-11-27 US disclosed
EP-1027359-A4 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS (US) 2001-07-25 EP disclosed
US-6130326-A Monocyclic L-Nucleosides, analogs and uses thereof ICN PHARMACEUTICALS, INC. (US) 2000-10-10 US disclosed
CN-1268140-A Monocyclic L-nucleosides, analogs and uses thereof ICN PHARMACEUTICALS (US) 2000-09-27 CN disclosed
EP-1027359-A2 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN Pharmaceuticals, Inc. (US) 2000-08-16 EP disclosed
US-5962457-A NERVOUS SYSTEM DISORDERS PFIZER INC. (US) 1999-10-05 US disclosed
EP-0900799-A1 Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones Pfizer Products Inc. (US) 1999-03-10 EP disclosed
WO-1998016186-A2 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS, INC. (US) 1998-04-23 WO disclosed
EP-0807633-A2 Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones PFIZER INC. (US) 1997-11-19 EP disclosed